Breaking News

Financial Report: Gilead

April 27, 2012

Product sales up 19%


1Q Revenues: $2.3 billion (+19%)

1Q Earnings: $437.5 million (-32%)

Comments: Revenue growth in the quarter was driven by increased sales of Atripla and Truvada, and the launch of Complera/Eviplera. Atripla sales increased 19% to $887.6 million and Truvada sales were up 13% to $758.3 million. Sales of Complera/Eviplera more than doubled to $52.2 million compared to 4Q11. Sales of Viread increased 14% to $191.7 million. Royalty, contract and other revenues from collaborations were $74.1 million in the quarter, up 19%. Earnings included $193.9 million of acquisition-related compensation expense related to the Pharmasset acquisition.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks